Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head AnalysisDefense World · 3 days ago
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx LaunchGlobeNewsWire · Oct 14, 2026
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” ConferenceGlobeNewsWire · Sep 2, 2026
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods TranscriptSeeking Alpha · Aug 17, 2026
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection TestingGlobeNewsWire · Aug 11, 2026
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 11, 2026OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.25 | -$0.31 | Miss |
| May 13, 2026 | -$0.26 | -$0.12 | Beat |
| Mar 26, 2026 | -$0.24 | -$0.72 | Miss |
| Nov 10, 2025 | -$0.21 | -$0.34 | Miss |
| Aug 14, 2025 | -$0.23 | -$0.30 | Miss |
| May 12, 2025 | -$0.24 | -$0.26 | Miss |